In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with substantial consequences for patients and their families and a significant impact on healthcare systems.
RECOGNISED (Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia) will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in the T2D population.
It will use this knowledge to characterise clinical phenotypes based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline.
The RECOGNISED project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847749.
